- Home
- Companies
- John Wiley & Sons, Ltd.
- Articles
- Optimising fluorescent protein choice ...
Optimising fluorescent protein choice for transgenic embryonic medaka models
Courtesy of John Wiley & Sons, Ltd.
Early life stage transgenic medaka are recognised as a pertinent model by the OECD and are non‐compliant with the European definition of a laboratory animal. However, auto‐fluorescence confounds readout of fluorescent biomarkers. We determined the fluorescence emission spectrum of different embryonic stages of medaka submitted to a range of excitation wavelengths. This allows selection of high signal to noise ratio fluorescent proteins and combining multiple biomarkers within a single embryo. Environ Toxicol Chem © 2013 SETAC
-
Most popular related searches
Customer comments
No comments were found for Optimising fluorescent protein choice for transgenic embryonic medaka models. Be the first to comment!